Projection de l'incidence et de la mortalité par cancer en France métropolitaine en 2017. Rapport technique, p.80, 2017. ,
Targeted Molecular Treatments in Non-Small Cell Lung Cancer : A Clinical Guide for Oncologists, J Clin Med, vol.7, issue.8, p.192, 2018. ,
Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma, Crit Rev Oncol Hematol, vol.88, pp.477-493, 2013. ,
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort, Ann Oncol, vol.27, issue.2, pp.281-286, 2016. ,
Role and targeting of anaplastic lymphoma kinase in cancer, Mol Cancer, vol.17, issue.1, p.30, 2018. ,
Crizotinib in ROS1-rearranged non-small-cell lung cancer, The New England Journal of Medicine, vol.371, pp.1963-1971, 2014. ,
KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies, Oncotarget, vol.7, issue.7, pp.8373-88, 2016. ,
Hallmarks of cancer: the next generation, Cell. 2011, vol.144, issue.5, pp.646-674 ,
The basics of epithelial-mesenchymal transition, J Clin Invest, vol.119, issue.6, pp.1420-1428, 2009. ,
Biomarkers of epithelialmesenchymal transition in squamous cell carcinoma, J Dent Res, vol.92, issue.2, pp.114-135, 2012. ,
EMT, CSCs, and drug resistance: the mechanistic link and clinical implications, Nat Rev Clin Oncol, vol.14, issue.10, pp.611-629, 2017. ,
Vimentin expression predicts the occurrence of metastases in non small cell lung carcinomas, Lung Cancer, vol.81, issue.1, pp.117-122, 2013. ,
The role of phenotypic plasticity in the escape of cancer cells from targeted therapy, Biochem pharmacol, vol.122, pp.1-9, 2016. ,
Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients, Clin Cancer Res, vol.11, issue.24, pp.8686-8698, 2005. ,
Epithelial-mesenchymal transition leads to crizotinib resistance in H2228 lung cancer cells with EML4-ALK translocation, Mol. Oncol, vol.7, pp.1093-1102, 2013. ,
CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib, Cancer Lett, vol.422, pp.19-28, 2018. ,
FHIT: from gene discovery to cancer treatment and prevention, Lancet Oncol, vol.3, issue.12, pp.748-754, 2002. ,
Fhit regulates invasion of lung tumor cells, Oncogene, vol.29, issue.8, pp.1203-1213, 2010. ,
URL : https://hal.archives-ouvertes.fr/inserm-00453584
FHIT suppresses epithelial-mesenchymal transition (EMT) and metastasis in lung cancer through modulation of microRNAs, PLoS Genet, vol.10, issue.10, p.1004652, 2014. ,
Fhit regulates EMT targets through an EGFR/Src/ERK/Slug signaling axis in human bronchial cells, Mol Cancer Res, vol.12, issue.5, pp.775-783, 2014. ,